JPWO2020136101A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020136101A5
JPWO2020136101A5 JP2021537716A JP2021537716A JPWO2020136101A5 JP WO2020136101 A5 JPWO2020136101 A5 JP WO2020136101A5 JP 2021537716 A JP2021537716 A JP 2021537716A JP 2021537716 A JP2021537716 A JP 2021537716A JP WO2020136101 A5 JPWO2020136101 A5 JP WO2020136101A5
Authority
JP
Japan
Prior art keywords
ppp
weeks
seq
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021537716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515480A (ja
JP2022515480A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/086521 external-priority patent/WO2020136101A1/en
Publication of JP2022515480A publication Critical patent/JP2022515480A/ja
Publication of JPWO2020136101A5 publication Critical patent/JPWO2020136101A5/ja
Publication of JP2022515480A5 publication Critical patent/JP2022515480A5/ja
Pending legal-status Critical Current

Links

JP2021537716A 2018-12-27 2019-12-20 掌蹠膿疱症の処置のための抗il-36r抗体 Pending JP2022515480A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862785316P 2018-12-27 2018-12-27
US62/785,316 2018-12-27
US201962815431P 2019-03-08 2019-03-08
US62/815,431 2019-03-08
US201962891464P 2019-08-26 2019-08-26
US62/891,464 2019-08-26
PCT/EP2019/086521 WO2020136101A1 (en) 2018-12-27 2019-12-20 Anti-il-36r antibodies for treatment of palmoplantar pustulosis

Publications (3)

Publication Number Publication Date
JP2022515480A JP2022515480A (ja) 2022-02-18
JPWO2020136101A5 true JPWO2020136101A5 (https=) 2022-12-21
JP2022515480A5 JP2022515480A5 (https=) 2022-12-21

Family

ID=69190739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537716A Pending JP2022515480A (ja) 2018-12-27 2019-12-20 掌蹠膿疱症の処置のための抗il-36r抗体

Country Status (14)

Country Link
US (3) US20200207862A1 (https=)
EP (1) EP3902604A1 (https=)
JP (1) JP2022515480A (https=)
KR (1) KR20210119407A (https=)
CN (1) CN113301955A (https=)
AU (1) AU2019416727A1 (https=)
BR (1) BR112021010789A2 (https=)
CA (1) CA3124996A1 (https=)
CL (1) CL2021001685A1 (https=)
IL (1) IL284259A (https=)
MX (1) MX2021007807A (https=)
PH (1) PH12021551540A1 (https=)
TW (1) TW202037604A (https=)
WO (1) WO2020136101A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
EP4182022A1 (en) * 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
US20220119538A1 (en) * 2020-09-30 2022-04-21 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
BR112023017717A2 (pt) 2021-05-03 2024-01-09 Boehringer Ingelheim Int Método para produção de espesolimabe
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
EP4370550A1 (en) * 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
KR20250122528A (ko) * 2022-12-23 2025-08-13 아이코사백스, 인크. 메타뉴모바이러스 융합(f) 단백질에 대한 항체 및 그 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 il-36r 항체
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CN107660155B (zh) 2015-04-24 2021-02-02 艾斯曲尔医疗公司 药剂输送装置的子组件和药剂输送装置
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン36受容体アンタゴニスト欠損症の治療薬
CA3093692A1 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis

Similar Documents

Publication Publication Date Title
US20200040073A1 (en) Methods for administering anti-il-5 antibodies
US20230293682A1 (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r antagonist
JPWO2021183359A5 (https=)
US20230303678A1 (en) Methods for treatment of subjects with plaque psoriasis of the scalp
JP7357646B2 (ja) 乾癬の治療のための組成物及び方法
US8012478B2 (en) Use of anti-IL-20 antibody for treating stroke
JPWO2020136101A5 (https=)
US20240287170A1 (en) Methods for treating systemic sclerosis
US12583914B2 (en) Methods of treating allergy using anti-bet v 1 antibodies
US12509504B2 (en) Method of treating HBV infection by using anti-pre-S1 HBV antibodies
CN106573975A (zh) 抗il4‑il13双特异性抗体
US20250263471A1 (en) Methods of treating allergy using anti-bet v 1 antibodies
US20240092882A1 (en) Method of treating an allergy with allergen-specific monoclonal antibodies
JP2024177399A (ja) 呼吸器疾患の治療のための汎elr+cxcケモカイン抗体
TW201842933A (zh) 使用il-17拮抗劑選擇性治療氣喘的方法
CN118021955A (zh) 用于治疗il-17a介导的疾病或病症的方法和组合物
WO2024146630A1 (zh) 一种tslp抗体治疗哮喘的方法
WO2026078117A1 (en) Anti-il-5 antibody in the treatment of chronic rhinosinusitis with nasal polyps
WO2025242619A1 (en) Treatment for mucus plugging
TW202521154A (zh) 既往接受生物製劑治療斑塊狀銀屑病的受試者轉用抗IL23p19抗體治療斑塊狀銀屑病的方法
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
CN121909045A (zh) 一种重组抗IL-23p19抗体治疗中重度银屑病的方法
CN115916820A (zh) 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法
JPWO2022187851A5 (https=)